Crinetics Pharmaceuticals (CRNX) has initiated the BALANCE-CAH Phase 2/3 clinical trial, marking a significant step forward in the development of atumelnant. The first participant has been administered this investigational treatment, which is designed as a novel, oral therapy taken once daily. Atumelnant targets the adrenocorticotropic hormone receptor and is being evaluated for its effectiveness in treating classic congenital adrenal hyperplasia among pediatric and adolescent patients.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.